Showing results (41-50 of 56) with videos related to
Sort By:
Pageof 6
Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Societal cost savings through bevacizumab-based treatment in non-small cell lung cancer (NSCLC)Sanja Stanisic, Helge G Bischoff, David F Heigener, et al.Lung Cancer (Amsterdam, Netherlands)|August 24, 2010
Effectiveness of bevacizumab- and pemetrexed-cisplatin treatment for patients with advanced non-squamous non-small cell lung cancerMark Nuijten, David F Heigener, Helge G Bischoff, et al.Cancer|January 26, 2011
Combined treatment of nonsmall cell lung cancer NSCLC stage III with intensity-modulated RT radiotherapy and cetuximab: the NEAR trialAlexandra D Jensen, Marc W Münter, Helge G Bischoff, et al.International Journal of Obesity (2005)|June 16, 2011
Multicenter evaluation of an interdisciplinary 52-week weight loss program for obesity with regard to body weight, comorbidities and quality of life--a prospective studyS C Bischoff, A Damms-Machado, C Betz, et al.European Journal of Nuclear Medicine|January 1, 1985
Measurement of glomerular filtration rate using 99mTc-DTPA and the gamma camera: a comparison of methodsC D Russell, P G Bischoff, F Kontzen, et al.Journal of Biomolecular Structure & Dynamics|January 10, 2001
Biomesogenic matrix systemsW V Meister, S Lindau, A L Hauser, et al.Journal of Nuclear Medicine : Official Publication, Society of Nuclear Medicine|November 1, 1985
Measurement of glomerular filtration rate: single injection plasma clearance method without urine collectionC D Russell, P G Bischoff, F N Kontzen, et al.Clinical Nutrition ESPEN|January 7, 2026
Valid food intake measures of adult patients for use within the GLIM framework: a scoping reviewR Blaauw, G Bischoff, Mae de van der Schueren, et al.Investigational New Drugs|November 11, 2019
A phase 1 dose-escalation study of checkpoint kinase 1 (CHK1) inhibitor prexasertib in combination with p38 mitogen-activated protein kinase (p38 MAPK) inhibitor ralimetinib in patients with advanced or metastatic cancerJohanna C Bendell, Helge G Bischoff, Jimmy Hwang, et al.Lung Cancer (Amsterdam, Netherlands)|April 10, 2012
The gefitinib long-term responder (LTR)--a cancer stem-like cell story? Insights from molecular analyses of German long-term responders treated in the IRESSA expanded access program (EAP)Sandra Gottschling, Esther Herpel, Wilfried E E Eberhardt, et al.Pageof 6